A5044613951- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Chronic Lymphocytic Leukemia Research
- Cancer Research and Treatments
- Advanced Breast Cancer Therapies
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Estrogen and related hormone effects
- Glycosylation and Glycoproteins Research
- RNA modifications and cancer
Virginia Cancer Specialists
2016-2025
The US Oncology Network
2009-2024
Johns Hopkins Medicine
2020-2024
Johns Hopkins University
2002-2024
Chungbuk National University Hospital
2024
Samsung Medical Center
2024
Asan Medical Center
2024
Seoul National University Bundang Hospital
2024
Yonsei University
2024
National Cancer Institute
2024
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel experts medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, advocacy was convened to develop clinical practice guideline....
Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors a phase 1 study, and particularly promising was observed subgroup of non–small-cell lung cancer (NSCLC).
Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The of brigatinib, as compared crizotinib, advanced NSCLC who have not previously received an ALK inhibitor unclear.In open-label, phase 3 trial, we randomly assigned, 1:1 ratio, had inhibitors receive brigatinib at dose 180 mg once daily (with 7-day lead-in period 90 mg) or crizotinib 250 twice daily....
Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response patients non-small-cell lung cancer (NSCLC) treated EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib advanced NSCLC harboring and explored significance of mutation subtypes TKI resistance mechanisms.Chemotherapy-naïve >or= 1 clinical characteristic associated underwent direct DNA sequencing tumor tissue exons 18 to 21. Patients...
This multicenter study, to our knowledge, is the first phase III trial compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy an anthracycline and at least one additional systemic regimen.Patients were randomly assigned a 2:1 ratio receive intravenously every 3 weeks. The primary end point was overall survival (OS), secondary points disease control-progression-free (PFS), time progression, objective response rate, duration of...
We used the simian immunodeficiency virus (SIV)/rhesus macaque model to study events that underlie sexual transmission of human type 1 (HIV-1). Four female rhesus macaques were inoculated intravaginally with SIVmac251, and then killed 2, 5, 7, 9 d later. A technique detected polymerase chain reaction-amplified SIV in situ showed first cellular targets for lamina propria cervicovaginal mucosa, immediately subjacent epithelium. Phenotypic localization studies demonstrated many infected cells...
Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity had an acceptable adverse-event profile the phase 1–1b part of KRYSTAL-1 1–2 study.
To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.A multidisciplinary panel medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine, nursing, trialists, advocacy experts was convened to update guideline. Guideline development involved a systematic literature review an...
Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent selective ALK inhibitor excellent CNS penetration, patients crizotinib-refractory ALK-positive NSCLC.Alectinib 600 mg was administered orally twice daily. The primary end point objective response rate (ORR) by central independent...
Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody immune cell-directing activity, binds each receptor's extracellular domain, bypassing at the inhibitor binding site.CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included population EGFR Exon20ins NSCLC. The primary end...
Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We evaluated the of cabozantinib in patients castration-resistant prostate cancer (CRPC) a phase II randomized discontinuation trial expansion cohort.Patients received 100 mg daily. Those stable disease per RECIST at 12 weeks were randomly assigned to or placebo. Primary end points objective response rate progression-free survival (PFS) after...
Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501). We report results second prespecified (150...
Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining a epidermal growth factor receptor antibody could be effective strategy.In this phase 1-2, open-label, nonrandomized trial, we assigned heavily metastatic cancer to receive adagrasib monotherapy (600 mg orally twice daily) or (at the same dose) combination intravenous...
Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to long-term outcomes. Download a PDF the Research Summary. We randomly assigned NSCLC (stage II IIIB [N2 node stage] according eighth edition AJCC Cancer Staging Manual) receive platinum-based chemotherapy plus durvalumab placebo administered intravenously every 3 weeks for 4 cycles before surgery, followed by 12...
In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib 1st Line (ALTA-1L), which is a brigatinib inhibitor-naive advanced ALK-positive NSCLC, exhibited superior progression-free survival (PFS) versus crizotinib two planned interim analyses. Here, we report final efficacy, safety, and exploratory results.Patients were randomized to 180 mg once daily (7-d lead-in at 90 daily) or 250 twice daily. The primary end point was blinded independent review committee-assessed PFS. Genetic...
Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In phase study, an benefit in this population was observed the addition olaratumab to doxorubicin over alone.To determine efficacy plus patients advanced/metastatic STS.ANNOUNCE confirmatory, 3, double-blind, randomized trial conducted at 110 sites 25 countries from September 2015 December 2018; final date follow-up 5, 2018. Eligible were anthracycline-naive adults unresectable locally or...
Abstract Purpose: Here, we report results of the first phase I study erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening activating FGFR genomic alterations. In patients such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily 10 intermittently (7 days...
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non-small cell lung cancer, was evaluated a phase I/II dose-escalation/expansion trial (ClinicalTrials.gov NCT02716116). Dose escalation identified 160 mg/d as the recommended 2 dose and maximum tolerated dose. Among 136 patients treated with mg/d, most common any-grade treatment-related adverse events (TRAE; >25%) were diarrhea (83%), nausea...